ES2980790T3 - Acidos grasos estructuralmente mejorados que contienen azufre para su uso en el tratamiento de la esteatohepatitis no alcohólica - Google Patents

Acidos grasos estructuralmente mejorados que contienen azufre para su uso en el tratamiento de la esteatohepatitis no alcohólica Download PDF

Info

Publication number
ES2980790T3
ES2980790T3 ES16717933T ES16717933T ES2980790T3 ES 2980790 T3 ES2980790 T3 ES 2980790T3 ES 16717933 T ES16717933 T ES 16717933T ES 16717933 T ES16717933 T ES 16717933T ES 2980790 T3 ES2980790 T3 ES 2980790T3
Authority
ES
Spain
Prior art keywords
compound
use according
ester
compound according
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16717933T
Other languages
English (en)
Spanish (es)
Inventor
Hilde Steineger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF AS
Original Assignee
BASF AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF AS filed Critical BASF AS
Application granted granted Critical
Publication of ES2980790T3 publication Critical patent/ES2980790T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fats And Perfumes (AREA)
ES16717933T 2015-04-28 2016-04-21 Acidos grasos estructuralmente mejorados que contienen azufre para su uso en el tratamiento de la esteatohepatitis no alcohólica Active ES2980790T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20150514 2015-04-28
PCT/EP2016/058909 WO2016173923A1 (en) 2015-04-28 2016-04-21 Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis

Publications (1)

Publication Number Publication Date
ES2980790T3 true ES2980790T3 (es) 2024-10-03

Family

ID=55806346

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16717933T Active ES2980790T3 (es) 2015-04-28 2016-04-21 Acidos grasos estructuralmente mejorados que contienen azufre para su uso en el tratamiento de la esteatohepatitis no alcohólica

Country Status (10)

Country Link
US (5) US20180104201A1 (https=)
EP (1) EP3288550B1 (https=)
JP (3) JP6784696B2 (https=)
KR (2) KR102644400B1 (https=)
CN (2) CN115025079A (https=)
AU (2) AU2016256552B2 (https=)
BR (1) BR112017023164A2 (https=)
CA (1) CA2983377C (https=)
ES (1) ES2980790T3 (https=)
WO (1) WO2016173923A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017023164A2 (en) 2015-04-28 2018-07-24 Pronova Biopharma Norge As and method of preventing and / or treating non-alcoholic steatohepatitis in an individual in need thereof
EP3638221B1 (en) * 2017-06-16 2021-09-29 Avexxin AS Compositions and methods for treatment of a fibrotic disease
HRP20241643T1 (hr) 2017-12-06 2025-02-14 Basf As Derivati masnih kiselina za liječenje nealkoholnog steatohepatitisa
JP7508447B2 (ja) * 2018-05-23 2024-07-01 ノースシー セラピューティクス ベスローテン フェンノートシャップ 血糖制御を改善し、炎症性腸疾患を処置するための構造修飾脂肪酸
KR102186416B1 (ko) 2019-01-16 2020-12-07 서울대학교산학협력단 12-lox 발현 촉진제를 포함하는 간 질환 예방 또는 치료용 조성물
WO2022137125A1 (en) 2020-12-22 2022-06-30 Northsea Therapeutics B.V. Combination therapies comprising oxygen-containing structurally enhanced fatty acids for treatment of non-alcoholic steatohepatitis
KR20250136619A (ko) 2024-03-08 2025-09-16 주식회사 엘지에너지솔루션 배터리 관리 장치 및 방법

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909554A (en) 1956-07-23 1959-10-20 Monsanto Chemicals Process for the manufacture of (alkylmercapto) alkyl sulfates
GB1038723A (https=) 1962-03-26
JPS4839001B1 (https=) 1970-11-09 1973-11-21
US4040781A (en) 1974-06-06 1977-08-09 Lever Brothers Company Novel 2-(alkylsulfinyl)ethyl sulfates and compositions employing same
US4032564A (en) 1974-09-09 1977-06-28 Zoecon Corporation Esters of cyclopropylalkanols
GB1523276A (en) 1974-09-20 1978-08-31 Lafon Labor Sulphur-containing amino compounds
US4009211A (en) 1975-07-29 1977-02-22 Gulf Research & Development Company Beta,beta-dialkylethylmercaptoethoxylate as new compounds
US4209410A (en) 1976-04-28 1980-06-24 Phillips Petroleum Company Lubricants
DE2861974D1 (en) 1977-11-11 1982-09-16 Ciba Geigy Ag Pyridine dicarboxylic acid derivatives, their mixtures with metallic stabilisers and their use in stabilising chlorine-containing thermoplasts
JPS5570841A (en) 1978-11-24 1980-05-28 Konishiroku Photo Ind Co Ltd Forming method of dye image
US4368190A (en) 1980-04-17 1983-01-11 Merck & Co., Inc. Immunologically active dipeptidyl 4-O-,6-O-acyl-2-amino-2-deoxy-D-glucose derivatives and methods for their preparation
US4444766A (en) 1980-10-21 1984-04-24 Boehringer Mannheim Gmbh Sulfur-containing phospholipid compounds and therapeutic compositions
US4411808A (en) 1982-08-04 1983-10-25 Exxon Research & Engineering Co. Multifunctional additive for power transmission shift fluids
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4775223A (en) 1984-09-20 1988-10-04 Canon Kabushiki Kaisha Lactic acid derivative, liquid crystal composition containing same and liquid crystal device
CA2010000A1 (en) 1989-04-07 1990-10-07 Paul B. Merkel Photographic recording material containing a cyan dye-forming coupler
JPH0451149A (ja) 1990-06-19 1992-02-19 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
FR2663928B1 (fr) 1990-06-27 1994-04-08 Norsolor Nouveaux composes acryliques soufres, un procede pour leur preparation et leur application a la synthese de nouveaux polymeres.
EP0487809A1 (en) 1990-11-28 1992-06-03 Monsanto Europe S.A./N.V. Rubber compositions having improved processability and improved rubber-vulcanisate properties
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
JPH0543529A (ja) 1991-08-10 1993-02-23 Taisho Pharmaceut Co Ltd アルカンアミドアンモニウム化合物
JP2755279B2 (ja) 1992-03-19 1998-05-20 三井化学株式会社 熱可塑性樹脂組成物およびその成形体
JP2793458B2 (ja) 1992-03-19 1998-09-03 三井化学株式会社 コネクター用ポリアミド系樹脂組成物およびコネクター
EP0702556B1 (en) 1993-06-10 2002-10-23 Wake Forest University (phospho)lipids for combatting hepatitis b virus infection
JP3110918B2 (ja) 1993-06-18 2000-11-20 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
US5523430A (en) 1994-04-14 1996-06-04 Bristol-Myers Squibb Company Protein farnesyl transferase inhibitors
GB2290789B (en) 1994-07-01 1998-09-16 Ciba Geigy Ag Titanium and zirconium complexes of carboxylic acids as corrosion inhibitors
DE69524639T2 (de) 1994-10-13 2002-08-08 Peptech Ltd., North Ryde Modifizierte mehrfach ungesättigte fettsäuren
US7517858B1 (en) 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
FR2741619B1 (fr) 1995-11-28 1998-02-13 Pf Medicament Nouveaux derives de 2,3,5-trimethyl-4-hydroxy-anilides, leur preparation et leur application en therapeutique
JP2000508645A (ja) 1996-04-12 2000-07-11 ペプテック リミテッド ポリ不飽和脂肪酸を使用する免疫病の治療方法
US6060515A (en) 1997-01-24 2000-05-09 The Regents Of The University Of California Treatment of skin conditions by use of PPARα activators
WO1998032444A1 (en) 1997-01-24 1998-07-30 The Regents Of The University Of California USE OF FXR, PPARα AND LXRα ACTIVATORS TO RESTORE BARRIER FUNCTION, PROMOTE EPIDERMAL DIFFERENTIATION AND INHIBIT PROLIFERATION
AU4806497A (en) 1997-10-01 1999-04-23 Procter & Gamble Company, The Glyoxylic compound comprising one or more active ingredient
JPH11180929A (ja) 1997-12-19 1999-07-06 Asahi Glass Co Ltd エステル誘導体
WO1999058120A1 (en) 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
FR2786187B1 (fr) 1998-11-19 2001-11-09 Univ Paris Curie Composes du type 2-acylamino-2-deoxy-glucono-1,5-lactone, procede d'obtention, compositions les comportant et utilisations
FR2792312B1 (fr) 1999-04-15 2001-06-08 Oreal Composes (poly)thia-alcynoiques et leurs derives, compositions les comprenant et leur utilisation
US6723717B1 (en) 1999-06-01 2004-04-20 The University Of Texas Southwestern Medical Center Sulfur-containing thyroxane derivatives and their use as hair growth promotors
EP1183074A1 (en) 1999-06-01 2002-03-06 University Of Texas Southwestern Medical Center Substituted biaryl ether compounds
NO328803B1 (no) 2000-03-03 2010-05-18 Thia Medica Nye fettsyreanaloger
UA75083C2 (uk) 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
FR2828487B1 (fr) 2001-08-09 2005-05-27 Genfit S A Nouveaux composes derives d'acides gras, preparation et utilisations
AU2002361850A1 (en) 2001-12-21 2003-07-30 3M Innovative Properties Company Medicinal aerosol formulations comprising ion pair complexes
GB2383355A (en) 2001-12-22 2003-06-25 Schlumberger Holdings An aqueous viscoelastic fluid containing hydrophobically modified polymer and viscoelastic surfactant
GB0202002D0 (en) 2002-01-29 2002-03-13 Leiv Eiriksson Nyotek A S Use
MXPA04007382A (es) 2002-01-31 2004-10-11 Tfl Ledertechnik Gmbh Composiciones y su uso para impartir repelencia al agua a cuero o pieles, textiles y otros materiales fibrosos.
WO2003105769A2 (en) 2002-06-13 2003-12-24 New York University Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
FR2845991B1 (fr) 2002-10-16 2005-02-04 Pf Medicament Derives d'alpha-phenyl acetanilides et leur application en therapeutique humaine
US8372430B2 (en) 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
EP1600438A4 (en) 2003-02-28 2007-05-02 Kaneka Corp METHODS FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS COMPRISING SUBSTITUENTS IN POSITION 2
DE10326303A1 (de) 2003-06-11 2004-12-30 Celares Gmbh Reagenzien zur Modifikation von Biopharmazeutika, deren Herstellung und Anwendung
CA2554735A1 (en) 2004-01-30 2005-08-11 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
JP4563114B2 (ja) 2004-08-30 2010-10-13 出光興産株式会社 潤滑剤用添加剤
US20060252670A1 (en) 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
JP2008532971A (ja) 2005-03-08 2008-08-21 チバ ホールディング インコーポレーテッド 特定のホスホネートにより被覆された金属酸化物ナノ粒子
CN101213281B (zh) 2005-05-04 2013-03-13 普罗诺瓦生物医药挪威公司 新的dha衍生物及其作为药物的用途
JP2008540394A (ja) 2005-05-04 2008-11-20 プロノヴァ バイオファーマ ノルゲ アクティーゼルスカブ 脂肪酸組成物、即ち、ｄｈａ誘導体の医薬としての使用
JP4315134B2 (ja) 2005-07-06 2009-08-19 セイコーエプソン株式会社 電子機器
US20070167529A1 (en) 2006-01-17 2007-07-19 Walton Rebecca A Antimicrobial compositions for treating fabrics and surfaces
US8987329B2 (en) 2006-04-12 2015-03-24 Conopco, Inc. Oral composition comprising a polyunsaturated fatty acid and salicylic acid for obtaining an antiinflammatory effect in skin
EP1849449A1 (en) 2006-04-26 2007-10-31 3M Innovative Properties Company Filler containing composition and process for production and use thereof
US7763607B2 (en) 2006-04-27 2010-07-27 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
CN101489544A (zh) 2006-05-09 2009-07-22 海玛奎斯特医药公司 治疗血液病的方法
WO2008132552A2 (en) 2006-11-01 2008-11-06 Pronova Biopharma Norge As Omega-3 lipid compounds
KR101438177B1 (ko) 2006-11-01 2014-09-05 프로노바 바이오파마 너지 에이에스 페록시솜 증식자-활성화 수용체의 활성자 또는 조절자인 알파-치환된 오메가-3 지질
WO2008053340A1 (en) 2006-11-03 2008-05-08 Pronova Biopharma Norge As A combination product comprising at least one lipid substituted in the alpha position and at least one hypoglycemic agent
CN101225064A (zh) 2007-01-19 2008-07-23 上海汇瑞生物科技有限公司 一种制备β-硫杂-α-烷基脂肪酸的新方法
DE102007017179A1 (de) 2007-04-12 2008-10-23 Clariant International Ltd. Verfahren zur Herstellung von Alkylpolyglykolcarbonsäuren und Polyglykoldicarbonsäuren mittels Direktoxidation
EP2217558A1 (en) 2007-10-31 2010-08-18 Pronova Biopharma Norge AS New dha derivatives and their use as medicaments
JP5620272B2 (ja) 2007-11-09 2014-11-05 プロノヴァ・バイオファーマ・ノルゲ・アーエスＰｒｏｎｏｖａ ＢｉｏＰｈａｒｍａ ＮｏｒｇｅＡＳ 化粧品において，食品サプリメントとして，または医薬品として用いるための脂質化合物
PE20100156A1 (es) 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
WO2009149496A1 (en) 2008-06-10 2009-12-17 Central Northern Adelaide Health Service Treatment of diabetes and complications thereof and related disorders
FR2933006B1 (fr) 2008-06-27 2010-08-20 Inst Francais Du Petrole Solution absorbante contenant un inhibiteur de degradation soufre a groupement carboxyle et methode pour limiter la degradation d'une solution absorbante
EP2315740B1 (en) 2008-07-08 2017-10-25 Catabasis Pharmaceuticals, Inc. Fatty acid acetylated salicylates and their uses
EP2147910A1 (en) * 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
SG175401A1 (en) 2009-05-08 2011-12-29 Pronova Biopharma Norge As Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
EP2248798A1 (en) 2009-05-08 2010-11-10 Pronova BioPharma Norge AS Novel lipid compounds
CA2772618C (en) 2009-09-01 2018-08-21 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
JP2013517322A (ja) 2010-01-20 2013-05-16 プロノヴァ・バイオファーマ・ノルゲ・アーエス サリチレート脂肪酸誘導体
MY170076A (en) 2010-11-05 2019-07-03 Pronova Biopharma Norge As Methods of treatment using lipid compounds
WO2012115695A1 (en) 2011-02-25 2012-08-30 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses
WO2014045293A1 (en) 2012-09-24 2014-03-27 Krisani Bioscience (P) Ltd. Fatty acid amides with a cysteamine or an acetylated cysteamine group and uses thereof
WO2013016531A2 (en) 2011-07-26 2013-01-31 Purdue Research Foundation Compounds and methods for use in treating neoplasia and cancer
US20130172244A1 (en) 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
HK1206248A1 (en) 2012-05-07 2016-01-08 Omthera Pharmaceuticals Inc. Compositions of statins and omega-3 fatty acids
WO2014057522A1 (en) 2012-10-12 2014-04-17 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
WO2014132134A1 (en) 2013-02-28 2014-09-04 Pronova Biopharma Norge As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
BR112016023269A8 (pt) 2014-04-11 2021-06-29 Cymabay Therapeutics Inc uso de ácido (r)-2-(4-((2-etóxi-3-(4-(trifluormetil)fenóxi)propil)-tio)-2-metilfenóxi)-acético ou sal do mesmo na fabricação de um medicamento para tratar doença hepática gordurosa não alcoólica ou esteato-hepatite não alcoólica
US20180110747A1 (en) 2015-04-01 2018-04-26 Pronova Biopharma Norge As Use of thia oxo compounds for lowering apo c3
BR112017023164A2 (en) 2015-04-28 2018-07-24 Pronova Biopharma Norge As and method of preventing and / or treating non-alcoholic steatohepatitis in an individual in need thereof
HRP20241643T1 (hr) 2017-12-06 2025-02-14 Basf As Derivati masnih kiselina za liječenje nealkoholnog steatohepatitisa

Also Published As

Publication number Publication date
JP6784696B2 (ja) 2020-11-11
JP2023116579A (ja) 2023-08-22
KR20240033300A (ko) 2024-03-12
EP3288550B1 (en) 2024-06-05
CA2983377C (en) 2023-08-29
US12465580B2 (en) 2025-11-11
KR102644400B1 (ko) 2024-03-06
CA2983377A1 (en) 2016-11-03
CN115025079A (zh) 2022-09-09
JP2018515463A (ja) 2018-06-14
US20180104201A1 (en) 2018-04-19
US20200085772A1 (en) 2020-03-19
JP2021035956A (ja) 2021-03-04
AU2021204406A1 (en) 2021-07-22
WO2016173923A1 (en) 2016-11-03
CN107530306A (zh) 2018-01-02
AU2016256552B2 (en) 2021-04-01
US20190314304A1 (en) 2019-10-17
JP7524411B2 (ja) 2024-07-29
US20240156760A1 (en) 2024-05-16
US11234948B2 (en) 2022-02-01
BR112017023164A2 (en) 2018-07-24
AU2021204406B2 (en) 2023-08-10
US20220280459A1 (en) 2022-09-08
AU2016256552A1 (en) 2017-11-16
KR20170140376A (ko) 2017-12-20
EP3288550C0 (en) 2024-06-05
US11911354B2 (en) 2024-02-27
US10722481B2 (en) 2020-07-28
EP3288550A1 (en) 2018-03-07

Similar Documents

Publication Publication Date Title
ES2980790T3 (es) Acidos grasos estructuralmente mejorados que contienen azufre para su uso en el tratamiento de la esteatohepatitis no alcohólica
ES2618604T3 (es) Métodos de tratamiento usando compuestos lipídicos
JP5620272B2 (ja) 化粧品において，食品サプリメントとして，または医薬品として用いるための脂質化合物
AU2010244136A1 (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
ES2889874T3 (es) Tratamiento de neuropatía óptica y reducción del estrés oxidativo inducido por esteroides con sustancias polinsaturadas estabilizadas
JP2010508261A (ja) 新規脂質化合物
US20240116864A1 (en) Xanthophyll derivatives
KR20180037915A (ko) 하이드록시-트리글리세라이드의 합성 방법 및 질병의 예방 및 치료에 사용되는 하이드록시-트리글리세라이드의 용도
GB2504061A (en) Omega-6 Enriched PUFA Phospholipids
BR102015007435A2 (pt) uso de compostos tia oxo para diminuir apo c3
CA2886957A1 (en) Use of thia oxo compounds for lowering apo c3